DEF: Elicio Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Elicio Therapeutics announces its annual stockholders meeting to be held virtually on May 19, 2025, featuring the election of directors and ratification of the company's independent accounting firm.

Summary

• Elicio Therapeutics will hold its Annual Meeting of Stockholders virtually on May 19, 2025, at 10:30 a.m. Eastern Time.
• Stockholders will vote on the election of Karen Wilson and Robert R. Ruffolo, Jr., Ph.D., FCPP, to the Board of Directors for terms expiring in 2028.
• The selection of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, will be up for ratification.
• The record date for determining stockholders eligible to vote is March 24, 2025.
• Stockholders can vote online during the meeting or by proxy via internet, telephone, or mail.
• The Board of Directors recommends voting FOR the election of the director nominees and FOR the ratification of Baker Tilly US, LLP.
• In 2024, Audit fees paid to Baker Tilly US, LLP were $567,800 and tax fees were $35,747.
• The company's Board of Directors consists of eight members, with five determined to be independent.
• The company has a Clawback Policy to recover incentive compensation from covered officers in the event of an accounting restatement.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive tone due to the expression of gratitude for stockholder support and anticipation of the annual meeting.

Positives

• The company is providing a virtual meeting format to enhance stockholder access and participation.
• The Board of Directors has a majority of independent directors.
• The company has a clear policy for handling related party transactions.
• The company has a Clawback Policy to recover incentive compensation from covered officers in the event of an accounting restatement.

Negatives

• The company's Board of Directors is divided into three classes with staggered three-year terms, which may delay or prevent a change of management or control.
• Directors may be removed only for cause by the affirmative vote of the holders of at least two-thirds of the voting power of the then outstanding voting stock.

Risks

• The classified board structure may delay or prevent a change of management or control of the company.
• The document mentions legal proceedings, but does not provide any details.

Future Outlook

The Board of Directors will reconsider the selection of Baker Tilly US, LLP if stockholders fail to ratify the selection, but may appoint different independent auditors at any time if it determines such a change would be in the best interests of Elicio and its stockholders.

Management Comments

• Robert Connelly, Chief Executive Officer and President: 'Thank you for your continued support of Elicio. We look forward to seeing you virtually at the Annual Meeting.'

Industry Context

The document reflects standard corporate governance practices for a publicly traded biopharmaceutical company, including the election of directors, selection of an independent auditor, and policies on related party transactions and insider trading.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity grants, is generally in line with industry practices for similarly sized biopharmaceutical companies.
• The virtual format of the annual meeting aligns with a growing trend among public companies to enhance accessibility and reduce costs.
• The company's clawback policy is consistent with regulatory requirements under the Dodd-Frank Act and Nasdaq listing standards.

Management Changes

Corporate Governance

Related Party Transactions

• In December 2023, Elicio entered into a subscription agreement with GKCC, LLC, an entity controlled by Yekaterina (Katie) Chudnovsky, a member of our Board of Directors, for the issuance and sale of 1,213,000 shares of common stock at $5.81 per share.
• In March 2024, Elicio entered into a subscription agreement with GKCC, LLC for the issuance and sale of pre-funded warrants to purchase up to 1,032,702 shares of common stock at $5.81 per warrant.
• In July 2024, Yekaterina (Katie) Chudnovsky purchased 1,600,000 July Pre-Funded Warrants and accompanying July Common Warrants for an aggregate purchase price of $7,984,000 and Jay Venkatesan and his affiliated trusts purchased 200,000 July Pre-funded Warrants and accompanying July Common Warrants for an aggregate purchase price of $998,000.
• In August 2024, Elicio issued a 3.0% Senior Secured Convertible Promissory Note due February 15, 2026 in the principal amount of $20.0 million to GKCC, LLC.
• In April 2025, Ms. Chudnovsky made a gift to us in the amount of $640,757 to be used for purposes of the continued development and manufacturing of our product candidates.

Stakeholder Impact

• Stockholders have the opportunity to participate in the governance of the company through voting on key proposals.
• The election of directors and ratification of the auditor directly impact the oversight and financial integrity of the company.
• Executive compensation policies and the clawback policy affect the alignment of management's interests with those of the stockholders.
• The company's commitment to corporate governance and ethical conduct benefits all stakeholders, including employees, customers, and suppliers.

Next Steps

• Stockholders are encouraged to vote promptly by proxy.
• Stockholders can pre-register for the virtual Annual Meeting at web.viewproxy.com/ELTX/2025.
• The company will file a Form 8-K to publish the final voting results within four business days after the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Stockholders, Baker Tilly, Corporate Governance, Executive Compensation, Elicio Therapeutics